Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
June 4, 2026
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
June 1, 2026
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
May 13, 2026
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
April 29, 2026
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
March 13, 2026